Tricida Supports the National Kidney Foundation in Asking “Are You the 33%?”
March 12 2020 - 9:00AM
Business Wire
Take the Kidney Risk Quiz at
MinuteForYourKidney.Org
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused
on the development and commercialization of its drug candidate,
veverimer (TRC101), a non-absorbed, orally-administered polymer
designed to treat metabolic acidosis in patients with chronic
kidney disease (CKD), today announced that it is an executive
sponsor of the National Kidney Foundation’s (NKF’s) newest public
awareness campaign which focuses on the 33 percent of American
adults at risk for developing dangerous, life-threatening kidney
disease. The NKF would like you to dedicate one minute of your day
to take the Kidney Risk Quiz. In just 60 seconds, you can find out
if you are the 1 in 3 American adults at risk for developing kidney
disease and learn what to do next to address your kidney
health.
“We are very pleased to support the NKF for leading this
initiative to help identify patients at risk for CKD,” said Gerrit
Klaerner, Ph.D., Tricida’s Chief Executive Officer and President.
“Over 37 million people are affected by kidney disease in the
United States, and sadly, most are undiagnosed. The serious
complications of kidney disease cannot be overstated, and we are
proud to contribute to this effort. We urge everyone to spend just
60 seconds to take the Kidney Risk Quiz.”
The first step to preventing kidney failure is knowing your risk
by taking the quiz. If it shows you may be at risk, two simple
tests, one blood and one urine, can let your doctor know how your
kidneys are doing. It’s easy to get tested and the results can save
your life. The “Are You the 33%” campaign microsite, public
service announcement and all creative assets will also be available
in Spanish starting September 15th for National Hispanic Heritage
Month. Go to MinuteForYourKidneys.org to take the quiz and learn
more.
“We are very grateful for the collaboration with Tricida on this
major public awareness campaign,” said Anthony Gucciardo, Senior Vice
President, Strategic Partnerships, National Kidney Foundation. “Our
goal with the campaign is to reach the at-risk population so that
people can be diagnosed early and stave off the devastating
complications of this disease. With dedicated support from
corporate sponsors like Tricida, we’re making great strides towards
that goal.”
About CKD
CKD is a serious condition characterized by the gradual loss of
essential kidney functions over time. In patients with CKD, normal
fluid and electrolyte balance can no longer be maintained, and the
excretion of metabolic end products, toxins and drugs is impaired.
Furthermore, production and secretion of certain enzymes and
hormones are disturbed. According to the Centers for Disease
Control and Prevention, or CDC, more than 37 million people in the
United States are afflicted with CKD, representing an overall
prevalence in the adult population of approximately 15%. The
incidence of CKD is primarily driven by the increasing prevalence
of diabetes and hypertension. The treatment of CKD adds a
tremendous financial burden to the United States, with annual
Medicare expenses for CKD in 2018 totaling approximately $114
billion, including approximately $79 billion on CKD costs and
approximately $35 billion for end-stage renal disease, or ESRD,
costs. ESRD is total and permanent kidney failure that is treated
with kidney dialysis or with a kidney transplant. There are
approximately 750,000 people in the United States living on kidney
dialysis or with a kidney transplant and approximately 125,000 new
ESRD cases occur annually. Each year kidney disease kills more
people than breast cancer or prostate cancer. According to the 2019
United States Renal Data System report, there were approximately
105,000 deaths from ESRD in 2017. There is a significant medical
need to slow progression of kidney disease and reduce the number of
patients progressing to kidney failure.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its drug candidate, veverimer
(TRC101), a non-absorbed, orally-administered polymer designed to
treat metabolic acidosis in patients with CKD. Metabolic acidosis
is a condition commonly caused by CKD that is believed to
accelerate the progression of kidney deterioration. It is estimated
to pose a health risk to approximately three million patients with
CKD in the United States. Tricida is currently conducting its
confirmatory postmarketing trial, VALOR-CKD, of veverimer. The
Tricida New Drug Application (NDA) for veverimer has been accepted
for review by the U.S. Food and Drug Administration (FDA) through
the Accelerated Approval Program. The FDA has assigned a
Prescription Drug User Fee Act (PDUFA) goal date of August 22,
2020.
For more information about Tricida, please visit
www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements,
including for example, the potential timing for commercial launch
of veverimer, the assigned PDUFA goal date of August 22, 2020, and
the potential availability of the Accelerated Approval Program.
Forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. These risks
and uncertainties include, among others, that we may not be able to
achieve upcoming milestones; the cost, timing and results of
clinical trials and other studies; that many drug candidates that
have completed Phase 3 trials do not become approved drugs on a
timely or cost effective basis, or at all; there can be no
assurance that the FDA would approve an NDA through the Accelerated
Approval Program, or at all, and even if approval for a drug is
obtained, there can be no assurance that it will be adopted in the
market or accepted as a benefit to patients and healthcare
providers; possible safety and efficacy concerns; and that we
completely rely on third-party suppliers and manufacturers for many
aspects of our business. These and other factors that may affect
our future results of operations are identified and described in
more detail in our filings with the Securities and Exchange
Commission (SEC), including our Quarterly Reports on Form 10-Q and
our Annual Report on Form 10-K. The forward-looking statements
contained in this press release reflect Tricida’s current views
with respect to future events, and Tricida does not undertake and
specifically disclaims any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200312005273/en/
Jackie Cossmon, IRC Tricida, Inc. Senior Vice President of
Investor Relations and Communications IR@Tricida.com
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Sep 2023 to Sep 2024